Continued access study for tinengotinib in advanced solid tumors
Part of Cancer clinical trials.
This trial lets people who are already taking the study drug tinengotinib in another study keep getting it for as long as it helps them. It's for those who haven't stopped the drug and are still seeing benefits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently taking part in a TransThera-sponsored study for tinengotinib alone.
- You are still getting benefit from the treatment, according to your doctor.
- You have not permanently stopped taking tinengotinib for any reason other than joining this study.
- You meet all the rules for continuing treatment in your current study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people who are already taking the targeted therapy sotorasib (with or without another drug called panitumumab) in an Amgen clinical trial and are still doing well. It lets you keep receiving the same treatment after your original study ends, so you don't have to stop a medicine that is working for you.
This study lets people who are already benefiting from the cancer drug tucatinib keep taking it after their original study ends. It aims to provide continued access to the treatment while monitoring safety and effectiveness.
This study lets people who were already getting encorafenib and binimetinib in an earlier trial keep taking these medicines if they are doing well on them. It provides a way to continue treatment without a gap.
This study lets people who finished a prior dabrafenib/trametinib trial (sponsored by Novartis or former GSK) continue those medicines if the study doctor thinks it will help. It mainly focuses on ongoing treatment benefit rather than testing a new drug.
This is a “rollover” study for people who were already taking a Roche (or Genentech) cancer study medicine. It checks whether continuing the same study treatment (when commercial options aren’t available) can keep helping you.
This trial offers continued access to the study drug catequentinib (AL3818) for people who were already taking it in an earlier Advenchen study. It aims to see if you can keep benefiting from the treatment after the original trial ends.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.